---
title: "KAIRUIDE: Net loss of 20.4075 million yuan in the first half of 2025"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/255229332.md"
description: "KAIRUIDE announced that its operating revenue in the first half of 2025 was 259 million yuan, a year-on-year decrease of 20.99%. The net loss was 20.4075 million yuan, compared to a net profit of 4.6086 million yuan in the same period last year"
datetime: "2025-08-29T13:50:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/255229332.md)
  - [en](https://longbridge.com/en/news/255229332.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/255229332.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/255229332.md) | [繁體中文](https://longbridge.com/zh-HK/news/255229332.md)


# KAIRUIDE: Net loss of 20.4075 million yuan in the first half of 2025

KAIRUIDE announced that its operating revenue in the first half of 2025 was 259 million yuan, a year-on-year decrease of 20.99%. The net loss was 20.4075 million yuan, compared to a net profit of 4.6086 million yuan in the same period last year

### Related Stocks

- [KAIRUIDE (002072.CN)](https://longbridge.com/en/quote/002072.CN.md)

## Related News & Research

- [Aspen Pharmacare aims for Canada entry with Ozempic generic by third quarter](https://longbridge.com/en/news/277631988.md)
- [Trump on Iran: Have knocked out 10 ships](https://longbridge.com/en/news/277499993.md)
- [Asia high-sulphur fuel oil crack to Dubai flips into premium as Mideast tensions expected to tighten exports](https://longbridge.com/en/news/277432401.md)
- [08:03 ETDecentralized Clinical Trial Validates Novel "Fasting Mimetic" Formulation for Cardiometabolic Health](https://longbridge.com/en/news/277468910.md)
- [FEMA releasing billions in disaster assistance, while further funds await approval](https://longbridge.com/en/news/277255566.md)